{"disease":{"id":"treatment-of-gastroesophageal-reflux-disease-gerd","name":"treatment of gastroesophageal reflux disease gerd"},"drugs":{"marketed":[{"drug_id":"palazestrant","indication_name":"Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palazestrant","generic_name":"palazestrant","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor antagonist and degrader","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}